Authors





Lisa Carter-Bawa PhD, MPH, APRN, ANP-C, FAAN

Latest:

Combatting Stigmatization to Increase Lung Cancer Screening Access

Lisa Carter-Bawa PhD, MPH, APRN, ANP-C, FAAN, discusses how LungTalk, a health communication and decision support tool, may spread awareness and knowledge surrounding lung cancer screening.


Brandon Blue, MD

Latest:

Multiple Myeloma: Unmet Needs and Future Perspectives

Closing out their discussion on the management of multiple myeloma, experts from the Moffit Cancer Center highlight key unmet needs and future directions in care.



Neil M. Iyengar, MD

Latest:

Recent ADC Approvals and Their Impact on the Breast Cancer Space

Neil M. Iyengar, MD, highlighted the recent T-DXd and Dato-DXd approvals in breast cancer.


Kathleen Dorritie, MD

Latest:

Future Perspectives and Unmet Needs in Multiple Myeloma

The expert panel concludes their discussion by examining the unmet needs and future for the treatment landscape in multiple myeloma.


Chris Ryan

Latest:

Givastomig Regimen Yields Preliminary Activity in Gastric/GEJ Cancers

Phase 1b data show antitumor activity with the givastomig combination across a wide range of CLDN18.2 expression.



Jennifer L. Garson, PA-C

Latest:

Physician Assistant Perspectives: When to Consider Tazemetostat in R/R FL

A panelist discusses how tazemetostat offers a convenient, mutation-independent oral option for third-line follicular lymphoma treatment, balancing efficacy and tolerability while addressing patient lifestyle and financial considerations in an era of advanced therapies like CAR T-cell and bispecific antibodies.



Michelle Sittig, RN, OCN

Latest:

Complex ES-SCLC Case: Tarlatamab Management Through Toxicity to Clinical Benefit

Panelists discuss how effective management of cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome in complex extensive-stage small cell lung cancer (ES-SCLC) cases treated with tarlatamab enables patients to continue therapy and achieve meaningful clinical benefit despite early toxicities.





Catherine Watson, MD

Latest:

Catherin Watson, MD, Assesses the Future of Genetic Testing in Ovarian Cancer

At SGO 2022, Catherine Watson, MD, spoke about how to encourage patients with ovarian cancer to seek genetic testing.




Douglas Miller, MD

Latest:

A Rare Case of Glioblastoma With Extensive Liver Metastases

Ghulam Gous, MD, and colleagues report a case of glioblastoma with extensive liver metastases along with a review of previous reports of liver metastasis from glioblastomas and the possible mechanisms of metastasis.


Jason Chang, MD

Latest:

Improving Outcomes in Non-Small Cell Lung Cancer: Future Directions in Care

Best treatment approaches for patients with advanced NSCLC in the context of individualized therapy and an evolving therapeutic landscape.




Muhammad Talha Waheed, MD

Latest:

Data Show Underutilization of Appendectomy in Appendix Cancer Population

A lack of guidelines, a loss of follow-up, and out-of-state procedures are all potential reasons for 26% of patients undergoing appendectomy.


Alissa S. Marr, MD

Latest:

Clinical Trial Eligibility and Outcomes in Patients With Metastatic NSCLC Treated Outside of Clinical Trials

These data support less restrictive clinical trial eligibility criteria for those with metastatic NSCLC. This is especially true regarding both targeted therapy and immunotherapy treatment regimens.


Urvi Shah, MD

Latest:

Future Perspectives: Treating Multiple Myeloma With Novel Regimens

An overview of what’s next, in terms of the use of various frontline treatment regimens, that include novel agents to manage patients with newly diagnosed multiple myeloma.



Cindy Ludovico, NP

Latest:

KRAS+ NSCLC: Treatment Management Strategies

This video segment discusses strategies for patient education and preparation for second-line treatment with RAS GTPase inhibitors, as well as therapeutic options to consider if a patient progresses on adagrasib.


Jing Yi, PA

Latest:

Exploring the Future of ctDNA and Novel Treatment Strategies

Panelists offer concluding perspectives on the future role of circulating tumor DNA in colorectal cancer management.